Quantcast
Last updated on April 25, 2014 at 1:22 EDT

Latest T helper cell Stories

2012-03-02 05:53:04

(Ivanhoe Newswire) — Good news! Researchers have discovered a promising new technique that potentially could turn immune system killer T cells into more effective weapons against infections and possibly cancer. “The technique involves delivering DNA into the immune system's instructor cells. The DNA directs these cells to overproduce a specific protein that jumpstarts important killer T cells, called CD8 T cells. These killer cells are typically repressed in patients who have...

2012-02-27 08:30:00

WORCESTER, Mass. and TORONTO, Feb. 27, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT.OB) announced today that Dr. Eric von Hofe, Ph.D., President of Generex subsidiary Antigen Express, Inc., will give a presentation at the upcoming Cancer Immunotherapy Summit to be held in Boston, MA February 27-29. The presentation, entitled "Recent Advances in Understanding the Immune System and the Role of Th cells," will be given Wednesday, February 29 at 9:45 am EST. The...

2012-02-27 07:24:19

Study in Nature Medicine could lead to novel therapy for cancer In a study published in Nature Medicine, Loyola researchers report on a promising new technique that potentially could turn immune system killer T cells into more effective weapons against infections and possibly cancer. The technique involves delivering DNA into the immune system's instructor cells. The DNA directs these cells to overproduce a specific protein that jumpstarts important killer T cells. These killer cells...

2012-02-18 01:44:16

What if we could engineer a liver or kidney from a patient's own stem cells? How about helping regenerate tissue damaged by diseases such as osteoporosis and arthritis? A new UCLA study bring scientists a little closer to these possibilities by providing a better understanding how tissue is formed and organized in the body. A UCLA research team discovered that migrating cells prefer to turn right when encountering changes in their environment. The researchers were then able to translate...

2012-02-01 07:00:00

WORCESTER, Mass. and TORONTO, Feb. 1, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that its wholly owned subsidiary, Antigen Express, Inc., has been awarded a Japanese Patent centering on its Ii-Key technology for the development of immunotherapeutic vaccines. A number of products developed with this technology are currently in clinical development. The patent helps to secure the novel Antigen Express vaccine technology platform in the...

2012-01-25 08:00:00

WORCESTER, Mass. and TORONTO, Jan. 25, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) announced today that it has secured two commitments for an aggregate capital raise of CA$3,600,000. This funding is structured as term loans of one year from private lenders secured by the Company's real estate. Interest on the loans is payable monthly at the rate of 10% per annum. "This capital infusion will permit the Company to advance its redevelopment plans, and to...

2012-01-19 13:40:27

In a study investigating immune response in cancer, researchers from Moffitt Cancer Center in Tampa, Fla., and the University of South Florida have found that interaction between the immune system's antigen-specific CD4 T cells and myeloid-derived suppressor cells (MDSC) - cells that play a major role in cancer-related immune suppression - dramatically change the nature of MDSC-mediated suppression. By contrast, the same effect was not observed when MDSCs interacted with the immune system's...

2012-01-17 08:30:00

WORCESTER, Mass. and TORONTO, Jan. 17, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that a detailed interview conducted at the BioTech Showcase 2012 during last week's JPMorgan Healthcare Conference in San Francisco with Dr. Eric von Hofe, Ph.D., President of Generex subsidiary Antigen Express, Inc., regarding the Antigen Express breast cancer vaccine, is available on the Stock News Now website (www.stocknewsnow.com) and on the Generex...

2012-01-09 06:00:00

RICHMOND, Calif., Jan. 9, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the initiation of two new Phase 2 clinical studies (SB-728-1101 and SB-728-902, Cohort 5) in its program to develop a "functional cure" for HIV/AIDS. Sangamo's ZFP Therapeutic(®)( )approach (SB-728-T) generates T-cells that are resistant to HIV infection using its zinc finger nuclease (ZFN) technology to permanently disrupt the DNA sequence encoding CCR5, a co-receptor used by HIV to...

2012-01-04 12:56:00

WORCESTER, Mass. and TORONTO, Jan. 4, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT) announced today that representatives of the Company's wholly-owned subsidiary, Antigen Express, Inc., will be in attendance at the 2012 JPMorgan Healthcare Conference in San Francisco from January 8 through 13. (Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b ) Representatives of Antigen Express will be available over the course of the conference to meet with prospective...